The pharmaceutical company’s revenue increased 19.1% to ₹371 crore from ₹311 crore. Earnings before interest, tax, depreciation and amortisation (EBITDA) rose 67.6% to ₹135.6 crore from ₹80.9 crore a year ago, while the EBITDA margin expanded sharply to 37% from 26%.
It posted a profit before tax of ₹133.2 crore during the quarter, compared with ₹78.5 crore in the year-ago period. Total expenses increased to ₹241.2 crore from ₹235.6 crore a year ago, largely due to higher employee benefits and other operating expenses.
ALSO READ | Redtape Q4 Results: Footwear maker sees 33% revenue growth, margin expands; Stock surges 16%
For FY26, the company reported revenue from operations of ₹1,408 crore, compared to ₹934.2 crore in the previous financial year. Annual net profit rose to ₹326.9 crore from ₹234.4 crore a year ago, while total comprehensive income stood at ₹326.6 crore.
The board recommended a final dividend of ₹45 per equity share for FY26. Including the interim and special dividend declared earlier in the year, the total dividend payout for FY26 stands at ₹205 per share. The final dividend, subject to shareholder approval, will be paid on or before September 25, 2026.
ALSO READ | Marksans Pharma Q4 Results: Stock jumps 12% after profit surges, margin expands
P&G Health said it continues to operate as a single reportable segment focused on pharmaceuticals. The company also noted that the implementation of the new labour codes from November 2025 is not expected to have a material financial impact based on its current assessment.
Shares of the company ended 1.12% lower at ₹5,662, ahead of the Q4 earnings result announcement on Tuesday, May 26. The stock has gained 9.4% over the last month, but has declined more than 1% year-to-date.
